Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of 3SBio Inc. (HKG: 1530), has announced that its Phase III clinical trial for the anti-IL-17A monoclonal antibody SSGJ-608 in moderate to severe plaque psoriasis has successfully met its primary efficacy endpoints, including PASI 75 and sPGA 0/1, as well as all key secondary endpoints such as PASI 90, PASI 100, and sPGA 0.
The trial results demonstrated statistically significant improvements in clinical efficacy across all dosage groups of SSGJ-608 compared to the placebo, indicating a marked reduction in skin lesions among patients. The findings also revealed a notable increase in the proportion of patients achieving PASI 75, sPGA 0/1, PASI 90, PASI 100, and sPGA 0, with a favorable safety profile.
SSGJ-608 functions by selectively binding to human IL-17A, neutralizing its activity and effectively inhibiting the release of inflammatory factors, thereby mitigating the biological effects of IL-17A.- Flcube.com
